Explore News By Topic

03/22/2020

Molecular Imaging Could Transform Management of People with Aggressive Cancer

VICTORIA, Australia, March 22, 2020: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for their patients, by determining the extent of disease spread at the time of diagnosis, a randomised... Read More

12/16/2019

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More

12/16/2019

Winship study sheds light on immune control of cancer

Issued by: Emory University Woodruff Health Sciences Center New findings could provide doctors with vital clues about how the immune system prevents cancer from recurring. The study from Winship Cancer Institute of Emory University looked at whether immune cells were present in tumor samples removed from patients with kidney and... Read More

08/22/2019

The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners

The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research institutions. They will receive a total of $2.5 million to support cross-disciplinary pioneering research toward the goal of finding a... Read More

07/23/2019

Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine

Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports. An emerging class of drugs are made up of a radioactive particle that... Read More

06/26/2019

Newly defined cancer driver is Fast, Furious and Loud

Original Press Release Issued by: University of Michigan Medicine ANN ARBOR, Michigan — The Fast and the Furious movie franchise meets the Fast N’ Loud television series to define an oncogene that drives 35% of prostate cancers. A new study from researchers at the University of Michigan Rogel Cancer Center... Read More

05/22/2019

Black men less likely than nonblack patients to adopt active surveillance for low-risk prostate cancer

Original Press Release Issued by: Dana-Farber Cancer Institute Overall active surveillance rates are up, though the increase is significantly smaller for black patients Black men may be deterred by both socioeconomic factors and providers’ hesitation given concern for underlying aggressive disease BOSTON – At a time when a growing number of... Read More

05/06/2019

Gene mutation discovery linked to very poor survival in prostate cancer patients

Original Press Release Issued by: ICR (The Institute of Cancer Research) Scientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival – and which could be used to pick out patients for especially intensive treatment. Men with mutations in... Read More

03/28/2019

Researchers Discover How a Gene Deletion Contributes to Prostate Cancer Growth

Original Press Release Issued by: Weill Cornell Medicine The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that... Read More

03/20/2019

CURE Media Group Adds the Prostate Cancer Foundation to Its Strategic Alliance Partnership Program

CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates, research and education, has added the Prostate Cancer Foundation (PCF) to its Strategic Alliance Partnership (SAP) program. “PCF works hard to fund and accelerate research for... Read More